Cargando…
Community level antibiotic utilization in India and its comparison vis-à-vis European countries: Evidence from pharmaceutical sales data
India was the largest consumer of antibiotics in 2010 in the world. Evidence suggests that countries with high per-capita antibiotic consumption have higher rates of antibiotic resistance. To control antibiotic resistance, not only reduction in antibiotic consumption is required, socio-economic fact...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192587/ https://www.ncbi.nlm.nih.gov/pubmed/30332450 http://dx.doi.org/10.1371/journal.pone.0204805 |
_version_ | 1783363926994452480 |
---|---|
author | Farooqui, Habib Hasan Selvaraj, Sakthivel Mehta, Aashna Heymann, David L. |
author_facet | Farooqui, Habib Hasan Selvaraj, Sakthivel Mehta, Aashna Heymann, David L. |
author_sort | Farooqui, Habib Hasan |
collection | PubMed |
description | India was the largest consumer of antibiotics in 2010 in the world. Evidence suggests that countries with high per-capita antibiotic consumption have higher rates of antibiotic resistance. To control antibiotic resistance, not only reduction in antibiotic consumption is required, socio-economic factors like access to clean water and sanitation, regulation of private healthcare sector and better governance are equally important. The key objective of this research was to investigate the five year trends in consumption of major antibiotic classes in India and compare them with European Surveillance of Antimicrobial Consumption Network (ESAC-Net) countries. We used Intercontinental Marketing Statistics (IMS) Health (now IQVIA) medicine sales audit data of antibiotic sales in the retail private sector (excluding the hospitals sector) in India. We then standardized dosage trends and assigned defined daily dose (DDD) to all formulations based on the ATC/DDD index. We expressed our data in standardized matrices of DDD per 1000 inhabitants’ per day (DID) to compare antibiotic use in India with ESAC-Net countries. The antibiotic use was plotted and reported by year and antibiotic class. Our main findings are—per capita antibiotic consumption in the retail sector in India has increased from 13.1 DID in 2008 to 16.0 DID in 2012—an increase of ~22%; use of newer class of antibiotics like carbapenems (J01DH), lincosamides (J01FF), glycopeptides (J01XA), 3(rd) generation cephalosporins (J01DD) and penicillin’s with beta-lactamase inhibitors has risen; and antibiotic consumption rates in India are still low as compared to ESAC-Net countries (16.0 DID vs. 21.54 DID). To conclude our study has provided the first reliable estimates of antibiotic use in the retail sector in India vis-à-vis ESAC-Net countries. In addition, our study could provide a reference point to measure the impact of interventions directed towards reducing antibiotic use. |
format | Online Article Text |
id | pubmed-6192587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-61925872018-11-05 Community level antibiotic utilization in India and its comparison vis-à-vis European countries: Evidence from pharmaceutical sales data Farooqui, Habib Hasan Selvaraj, Sakthivel Mehta, Aashna Heymann, David L. PLoS One Research Article India was the largest consumer of antibiotics in 2010 in the world. Evidence suggests that countries with high per-capita antibiotic consumption have higher rates of antibiotic resistance. To control antibiotic resistance, not only reduction in antibiotic consumption is required, socio-economic factors like access to clean water and sanitation, regulation of private healthcare sector and better governance are equally important. The key objective of this research was to investigate the five year trends in consumption of major antibiotic classes in India and compare them with European Surveillance of Antimicrobial Consumption Network (ESAC-Net) countries. We used Intercontinental Marketing Statistics (IMS) Health (now IQVIA) medicine sales audit data of antibiotic sales in the retail private sector (excluding the hospitals sector) in India. We then standardized dosage trends and assigned defined daily dose (DDD) to all formulations based on the ATC/DDD index. We expressed our data in standardized matrices of DDD per 1000 inhabitants’ per day (DID) to compare antibiotic use in India with ESAC-Net countries. The antibiotic use was plotted and reported by year and antibiotic class. Our main findings are—per capita antibiotic consumption in the retail sector in India has increased from 13.1 DID in 2008 to 16.0 DID in 2012—an increase of ~22%; use of newer class of antibiotics like carbapenems (J01DH), lincosamides (J01FF), glycopeptides (J01XA), 3(rd) generation cephalosporins (J01DD) and penicillin’s with beta-lactamase inhibitors has risen; and antibiotic consumption rates in India are still low as compared to ESAC-Net countries (16.0 DID vs. 21.54 DID). To conclude our study has provided the first reliable estimates of antibiotic use in the retail sector in India vis-à-vis ESAC-Net countries. In addition, our study could provide a reference point to measure the impact of interventions directed towards reducing antibiotic use. Public Library of Science 2018-10-17 /pmc/articles/PMC6192587/ /pubmed/30332450 http://dx.doi.org/10.1371/journal.pone.0204805 Text en © 2018 Farooqui et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Farooqui, Habib Hasan Selvaraj, Sakthivel Mehta, Aashna Heymann, David L. Community level antibiotic utilization in India and its comparison vis-à-vis European countries: Evidence from pharmaceutical sales data |
title | Community level antibiotic utilization in India and its comparison vis-à-vis European countries: Evidence from pharmaceutical sales data |
title_full | Community level antibiotic utilization in India and its comparison vis-à-vis European countries: Evidence from pharmaceutical sales data |
title_fullStr | Community level antibiotic utilization in India and its comparison vis-à-vis European countries: Evidence from pharmaceutical sales data |
title_full_unstemmed | Community level antibiotic utilization in India and its comparison vis-à-vis European countries: Evidence from pharmaceutical sales data |
title_short | Community level antibiotic utilization in India and its comparison vis-à-vis European countries: Evidence from pharmaceutical sales data |
title_sort | community level antibiotic utilization in india and its comparison vis-à-vis european countries: evidence from pharmaceutical sales data |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192587/ https://www.ncbi.nlm.nih.gov/pubmed/30332450 http://dx.doi.org/10.1371/journal.pone.0204805 |
work_keys_str_mv | AT farooquihabibhasan communitylevelantibioticutilizationinindiaanditscomparisonvisaviseuropeancountriesevidencefrompharmaceuticalsalesdata AT selvarajsakthivel communitylevelantibioticutilizationinindiaanditscomparisonvisaviseuropeancountriesevidencefrompharmaceuticalsalesdata AT mehtaaashna communitylevelantibioticutilizationinindiaanditscomparisonvisaviseuropeancountriesevidencefrompharmaceuticalsalesdata AT heymanndavidl communitylevelantibioticutilizationinindiaanditscomparisonvisaviseuropeancountriesevidencefrompharmaceuticalsalesdata |